Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
44.38
+0.80 (1.84%)
At close: Jun 18, 2026, 4:00 PM EDT
44.38
0.00 (-0.01%)
After-hours: Jun 18, 2026, 4:24 PM EDT

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Supernus Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $62.83. The average 1-year stock price forecast is 41.57% higher than the current stock price, while the lowest is $55 (+23.93%) and the highest is $66 (+48.72%).

Price Target: $62.83 (+41.57%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$55$62.83$64$66
Change+23.93%+41.57%+44.21%+48.72%

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy444444
Buy111111
Hold111111
Sell000000
Strong Sell000000
Total666666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Piper Sandler
Piper Sandler
Buy
Maintains
$66
BuyMaintains$66+48.72%Jun 4, 2026
Stifel Nicolaus
Stifel Nicolaus
Hold
Maintains
$55
HoldMaintains$55+23.93%May 6, 2026
TD Cowen
TD Cowen
Buy
Maintains
$65
BuyMaintains$65+46.46%May 6, 2026
Unknown Analyst
Jefferies
No rating
Jefferies
Buy
Maintains
$60$65
BuyMaintains$60$65+46.46%Mar 24, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$65
BuyMaintains$65+46.46%Feb 25, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
867.26M
from 718.95M
Increased by 20.63%
Revenue Next Year
1.02B
from 867.26M
Increased by 17.60%
EPS This Year
2.49
from 2.40
Increased by 3.82%
EPS Next Year
4.34
from 2.49
Increased by 74.66%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
579.78M667.24M607.52M661.82M718.95M867.26M
Revenue Growth
11.41%15.09%-8.95%8.94%8.63%20.63%
Gross Profit
504.71M580.02M432.15M475.12M538.16M764.63M
Gross Margin
87.05%86.93%71.13%71.79%74.85%88.17%
Operating Income
79.50M45.61M13.40M61.36M25.76M149.41M
Net Income
53.42M60.71M1.32M73.87M-38.55M25.20M
EPS
----2.402.49
EPS Growth
-----11.15%3.82%
Forward PE
15.7330.8415.3419.6519.3317.85
Free Cash Flow
116.37M89.54M161.71M155.22M101.29M118.60M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High872.5M
Avg867.3M
Low859.0M

Revenue Growth

Revenue Growth202620272028
High
21.4%
Avg
20.6%
Low
19.5%

EPS Forecast

EPS202620272028
High-
Avg2.49
Low-

EPS Growth

EPS Growth202620272028
High-
Avg
3.8%
Low-